Outlook Therapeutics (OTLK) FCF Margin (2015 - 2025)

Outlook Therapeutics (OTLK) reported FCF Margin of 13484.7% for Q3 2025, up 1805.62% quarter-over-quarter from 790.61% in Q2 2025.

Outlook Therapeutics (OTLK) FCF Margin (2015 - 2025) Analysis & Trends

Outlook Therapeutics (OTLK) has 6 years of FCF Margin data on file, last reported at 13484.7% in Q3 2025.

  • FCF Margin for Q3 2025 came in at 13484.7%, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was 660.17% (changed N/A YoY), and the FY2025 annual result was 3666.65%, changed N/A from the prior year.
  • FCF Margin rose to 13484.7% in Q3 2025 per OTLK's latest filing, from 790.61% in the prior quarter.
  • Over five years, FCF Margin peaked at 13484.7% in Q3 2025 and troughed at 790.61% in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Margin (Qtr)
1 Alterity Therapeutics 719,706.53 Bn 719,706.50 Bn - -
2 Belite Bio 55,800.00 Bn 55,800.00 Bn - -
3 Quantum Biopharma 18,182.30 Bn 18,182.29 Bn - -
4 Legend Biotech 3,154.00 Bn 3,153.71 Bn 242.10 Mn -3.98%
5 Akari Therapeutics 1,844.30 Bn 1,844.29 Bn - -
6 Evaxion A 1,567.96 Bn 1,567.94 Bn - -
7 Psyence Biomedical 251.43 Bn 251.42 Bn - -
8 Vertex Pharmaceuticals 112.56 Bn 105.31 Bn 2.59 Bn 43.35%
9 Abivax 94.37 Bn 94.37 Bn - -
10 Outlook Therapeutics 51.56 Mn 43.81 Mn -21,888.00 -

Historic Data

Download Data
DateValue
Sep 30, 2025 13,484.70%
Jun 30, 2025 -790.61%
Sep 30, 2019 -91.08%
Jun 30, 2019 -1,895.78%
Mar 31, 2019 -984.12%
Dec 31, 2018 -938.35%
Sep 30, 2018 -1,251.08%
Jun 30, 2018 -1,127.54%
Mar 31, 2018 -999.38%
Dec 31, 2017 -1,262.64%
Sep 30, 2017 1.93%
Jun 30, 2017 -1,920.45%
Mar 31, 2017 -1,375.27%
Dec 31, 2016 -1,933.89%
Sep 30, 2016 -2,161.82%
Jun 30, 2016 -3,332.90%
Mar 31, 2016 -704.72%
Dec 31, 2015 -1,244.00%
Sep 30, 2015 -2,891.14%
Jun 30, 2015 -1,044.51%